Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Lupin Limited
WARNING LETTER
•Lupin Limited•May 19, 2017

Lupin Limited – FDA Warning Letter, May 19, 2017

Record Details

The FDA issued a Warning Letter to Lupin Limited following inspections of their Goa (March-April 2017) and Indore (May 2017) drug manufacturing facilities, citing significant Current Good Manufacturing Practice (CGMP) violations, rendering their drug products adulterated.

At Lupin Goa, violations included inadequate investigation of Out-of-Specification (OOS) results, particularly invalidating initial OOS lab results without thorough investigation into manufacturing causes. Examples cited were an API assay failure where multiple retests confirmed the OOS result, yet it was invalidated as an "outlier," and content uniformity failures for tablets where laboratory error was surmised without conclusive evidence or investigation into manufacturing causes. The firm also failed to establish appropriate time limits for production phases, holding bulk materials for excessive periods without adequate hold time studies representative of commercial batch sizes.

At Lupin Indore, similar violations were identified: inadequate hold time studies for bulk materials, not representative of commercial operations, and invalidation of nearly all initial OOS results (134 of 139 from 2015-2016) by attributing them to laboratory error without thorough investigation into potential manufacturing causes. An example included discarding an OOS sample vial and invalidating results based on retests without investigating manufacturing issues.

The FDA noted these were repeat observations at both sites, indicating inadequate company-wide oversight. Lupin's responses were deemed insufficient, lacking comprehensive retrospective assessments and robust corrective actions.

Required

Company
Lupin Limited
Inspection date
May 19, 2017
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Amit Sareen
  • Srinivas Rao Kalakuntla
View Company Profile

ID · 599ebee1-c4b9-4c24-bb37-78025b54ea60

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.19221 CFR 211.111FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Lupin Limited
  • 483 - 2023-07-11July 11, 2023
  • 483 - 2020-01-10January 10, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lupin Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.